Edwards Lifesciences Corp (EW)vsSera Prognostics Inc (SERA)
EW
Edwards Lifesciences Corp
$82.67
+1.20%
HEALTHCARE · Cap: $48.01B
SERA
Sera Prognostics Inc
$2.03
+11.54%
HEALTHCARE · Cap: $70.82M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 7490764% more annual revenue ($6.07B vs $81,000). EW leads profitability with a 17.7% profit margin vs 0.0%. EW earns a higher WallStSmart Score of 55/100 (C).
EW
Buy55
out of 100
Grade: C
SERA
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-544.4%
Fair Value
$12.31
Current Price
$82.67
$70.36 premium
Intrinsic value data unavailable for SERA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 23.7%
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 76.6%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.
Bull Case : SERA
The strongest argument for SERA centers on Price/Book, Debt/Equity.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.
Bear Case : SERA
The primary concerns for SERA are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
EW profiles as a mature stock while SERA is a value play — different risk/reward profiles.
SERA carries more volatility with a beta of 1.02 — expect wider price swings.
EW is growing revenue faster at 13.3% — sustainability is the question.
EW generates stronger free cash flow (354M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 27/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Sera Prognostics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sera Prognostics Inc. is a pioneering healthcare company focused on advancing maternal-fetal health through innovative diagnostic solutions. Leveraging its proprietary biomarker platform, Sera developed the PreTRM test to assess the risk of preterm birth, enabling timely clinical interventions that can significantly improve pregnancy outcomes. With a strong emphasis on collaboration with healthcare providers, Sera is poised to lead the prenatal diagnostics market, enhancing both maternal health and overall societal well-being. The company's dedication to innovation not only aims to foster healthier pregnancies but also seeks to generate long-term value for its investors.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?